Moonlight Tx nets $5M in Series A round

With the investment, Georgia Tech-launched Moonlight Therapeutics will evaluate its first food allergy treatment in clinical trials.
 
How and why: Called MOON101, the treatment is a skin stamp (above) that delivers drugs through needles small enough to be painless. The platform’s first drug is aimed at people with peanut allergies.
 
What’s unique: MOON101 overcomes skin barriers to deliver an allergen to an area of the skin that has an abundance of immune cells. It’s a complex drug delivery system in a simple stamp that’s applied daily. 

The latest backers: Portal Innovations, Inc. co-led the investment round, with AllerFund and Invest Georgia also investing. Based in Chicago, Portal Innovations held its grand opening for its Georgia HQ on Sept. 24 in Atlanta.
 
Significance: Clinical trials for MOON101 can now begin sooner.
 
Read the Hypepotamus article on the investment >
See GRA’s recent feature on Moonlight Therapeutics >